GAL-201 as a Promising Amyloid-β-Targeting Small-Molecule Approach for Alzheimer's Disease Treatment: Consistent...

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Soluble amyloid-beta (Aβ) oligomers are key neurotoxic species in Alzheimer's disease (AD).
• Preventing Aβ oligomerization is a therapeutic strategy for AD.
• GAL-201 is an orally bioavailable dipeptide that modulates Aβ aggregation.

Purpose of the Study:

• To evaluate the neuroprotective effects of GAL-201 against Aβ toxicity.
• To investigate GAL-201's mechanism of action in preventing Aβ oligomer formation.
• To assess GAL-201's efficacy in an Alzheimer's disease mouse model.

Main Methods:

• In vitro studies using various Aβ isoforms (Aβ1-42, Aβ(p3-42), Aβ1-40, 3NTyr(10)-Aβ).
• Assessment of synaptic plasticity, spine morphology, and neuroinflammation (microglia, astrocytes).
• In vivo studies using the "tgArcSwe" AD mouse model to evaluate spatial learning and Aβ deposition.

Main Results:

• GAL-201 effectively prevents the formation of toxic Aβ oligomers by binding to misfolded monomers.
• Neuroprotective effects on synaptic plasticity were observed irrespective of Aβ modifications.
• GAL-201 demonstrated sustained efficacy, improved spine morphology, reduced neuroinflammation, and enhanced spatial learning in AD mice.
• GAL-201 promoted the formation of non-toxic Aβ aggregates, effectively clearing toxic oligomers.

Conclusions:

• GAL-201 neutralizes Aβ oligomer toxicity by detoxifying β-sheet monomers.
• GAL-201 exhibits significant therapeutic potential as a drug candidate for Alzheimer's disease.
• Further IND-enabling studies for GAL-201 are warranted based on preclinical data.